Jingda Xu

1.8k total citations
24 papers, 1.4k citations indexed

About

Jingda Xu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Jingda Xu has authored 24 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Oncology and 6 papers in Immunology. Recurrent topics in Jingda Xu's work include Multiple Myeloma Research and Treatments (4 papers), Bone health and treatments (3 papers) and Cancer Cells and Metastasis (3 papers). Jingda Xu is often cited by papers focused on Multiple Myeloma Research and Treatments (4 papers), Bone health and treatments (3 papers) and Cancer Cells and Metastasis (3 papers). Jingda Xu collaborates with scholars based in China, United States and Australia. Jingda Xu's co-authors include Qingquan Li, Zu‐De Xu, Wenjuan Wang, Jing Yang, Zhiqiang Liu, Xiuping Liu, Jin He, Xi-Xi Cao, Jianfei Qian and Yuhuan Zheng and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Blood.

In The Last Decade

Jingda Xu

23 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jingda Xu China 17 771 643 390 242 145 24 1.4k
Shweta Joshi United States 23 655 0.8× 382 0.6× 403 1.0× 239 1.0× 81 0.6× 48 1.5k
Natasha M. Savage United States 18 488 0.6× 557 0.9× 585 1.5× 161 0.7× 106 0.7× 79 1.4k
Da‐Liang Ou Taiwan 20 656 0.9× 508 0.8× 300 0.8× 320 1.3× 187 1.3× 53 1.3k
Callum M. Sloss United States 19 797 1.0× 915 1.4× 407 1.0× 103 0.4× 136 0.9× 48 1.4k
Maciej Kmieciak United States 24 849 1.1× 971 1.5× 876 2.2× 225 0.9× 108 0.7× 66 2.0k
Satoru Shinriki Japan 24 850 1.1× 568 0.9× 214 0.5× 309 1.3× 68 0.5× 59 1.5k
Steven Pirie‐Shepherd United States 19 815 1.1× 356 0.6× 190 0.5× 398 1.6× 102 0.7× 36 1.4k
Fotis Asimakopoulos United States 20 538 0.7× 557 0.9× 333 0.9× 194 0.8× 76 0.5× 40 1.3k
Slawomir Wojtowicz‐Praga United States 14 675 0.9× 738 1.1× 358 0.9× 560 2.3× 73 0.5× 20 1.6k
Christophe Lebœuf France 24 604 0.8× 443 0.7× 295 0.8× 297 1.2× 274 1.9× 74 1.6k

Countries citing papers authored by Jingda Xu

Since Specialization
Citations

This map shows the geographic impact of Jingda Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingda Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingda Xu more than expected).

Fields of papers citing papers by Jingda Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jingda Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingda Xu. The network helps show where Jingda Xu may publish in the future.

Co-authorship network of co-authors of Jingda Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Jingda Xu. A scholar is included among the top collaborators of Jingda Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jingda Xu. Jingda Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Jingda, et al.. (2025). RE: Post-diagnosis dietary and lifestyle factors and mortality outcomes among colorectal cancer patients: a meta-analysis. JNCI Journal of the National Cancer Institute. 117(11). 2401–2402.
2.
Yan, Jun, Qingnan Zhao, Konrad Gabrusiewicz, et al.. (2019). FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nature Communications. 10(1). 448–448. 91 indexed citations
3.
Zhang, Mingjun, Jin He, Zhiqiang Liu, et al.. (2015). Anti-β2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget. 6(11). 8567–8578. 23 indexed citations
4.
Liu, Zhiqiang, Jingda Xu, Jin He, et al.. (2015). Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget. 6(33). 34329–34341. 124 indexed citations
5.
He, Zhimin, Jin He, Zhiqiang Liu, et al.. (2014). MAPK11 in breast cancer cells enhances osteoclastogenesis and bone resorption. Biochimie. 106. 24–32. 24 indexed citations
6.
Li, Haiyan, Yong Lu, Jianfei Qian, et al.. (2014). Human Osteoclasts Are Inducible Immunosuppressive Cells in Response to T cell–Derived IFN-γ and CD40 Ligand In Vitro. Journal of Bone and Mineral Research. 29(12). 2666–2675. 29 indexed citations
7.
Havránek, Ondřej, Stefan Koehrer, Zhiqiang Wang, et al.. (2014). The B-Cell Receptor Is Required for Optimal Viability, Growth, and Chemotherapy Resistance of Diffuse Large B-Cell Lymphoma Cell Lines of the Germinal Center B-Cell Subtype. Blood. 124(21). 493–493. 3 indexed citations
8.
Liu, Zhiqiang, Jingda Xu, Jin He, et al.. (2014). A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood. 124(13). 2061–2071. 80 indexed citations
9.
Liu, Zhiqiang, Jingda Xu, Haiyan Li, et al.. (2013). Bone Marrow Stromal Cells Derived MCP-1 Reverses the Inhibitory Effects of Multiple Myeloma Cells on Osteoclastogenesis by Upregulating the RANK Expression. PLoS ONE. 8(12). e82453–e82453. 10 indexed citations
10.
He, Jin, Zhiqiang Liu, Yuhuan Zheng, et al.. (2012). p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction. Cancer Research. 72(24). 6393–6402. 69 indexed citations
11.
Lu, Yong, Sungyoul Hong, Haiyan Li, et al.. (2012). Th9 cells promote antitumor immune responses in vivo. Journal of Clinical Investigation. 122(11). 4160–4171. 262 indexed citations
12.
Cao, Xi-Xi, Jingda Xu, Jiawen Xu, et al.. (2010). RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway. Breast Cancer Research and Treatment. 126(3). 555–563. 42 indexed citations
13.
Li, Qingquan, Jingda Xu, Wenjuan Wang, et al.. (2009). Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer Cells. Clinical Cancer Research. 15(8). 2657–2665. 286 indexed citations
14.
Xu, Jingda, Xiaoli Liu, Jiawen Xu, et al.. (2009). RACK1: A superior independent predictor for poor clinical outcome in breast cancer. International Journal of Cancer. 127(5). 1172–1179. 64 indexed citations
15.
16.
Cao, Xi-Xi, Jingda Xu, Jiawen Xu, et al.. (2009). RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Research and Treatment. 123(2). 375–386. 55 indexed citations
17.
Liu, Xiuping, Dongyan Li, Xiaoli Liu, et al.. (2008). Comparison of chromosomal aberrations between primary tumors and their synchronous lymph-node metastases in intestinal-type gastric carcinoma. Pathology - Research and Practice. 205(2). 105–111. 5 indexed citations
18.
Li, Qingquan, Wenjuan Wang, Jingda Xu, et al.. (2007). Up‐regulation of CD147 and matrix metalloproteinase‐2, ‐9 induced by P‐glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Science. 98(11). 1767–1774. 51 indexed citations
19.
Li, Qingquan, Wenjuan Wang, Jingda Xu, et al.. (2007). Involvement of CD147 in regulation of multidrug resistance to P‐gp substrate drugs andin vitroinvasion in breast cancer cells. Cancer Science. 98(7). 1064–1069. 55 indexed citations
20.
Xu, Guoping, Zu‐De Xu, Bu‐Lang Gao, et al.. (2007). Cervical Actinomycosis with Spinal Cord Compression. Chemotherapy. 54(1). 63–66. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shweta Joshi Breakdown of academic impact, for papers by Natasha M. Savage Breakdown of academic impact, for papers by Da‐Liang Ou Breakdown of academic impact, for papers by Callum M. Sloss Breakdown of academic impact, for papers by Maciej Kmieciak Breakdown of academic impact, for papers by Satoru Shinriki Breakdown of academic impact, for papers by Steven Pirie‐Shepherd Breakdown of academic impact, for papers by Fotis Asimakopoulos Breakdown of academic impact, for papers by Slawomir Wojtowicz‐Praga Breakdown of academic impact, for papers by Christophe Lebœuf
Rankless by CCL
2026